BRAF and colorectal carcinoma: Another cholesterol-lowering drug, simvastatin, suppressed HNSCC growth ex vivo, enhanced the cytostatic effects of chemotherapeutics (cisplatin and docetaxel) [55], and even overcame CTX resistance in KRAS-mutant CRC by modulating BRAF activity [56].